Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Vaxart, Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
Vaxart appointed James B. Breitmeyer, M.D., Ph.D. to its Board of Directors on April 23, 2026, effective immediately. Dr. Breitmeyer, currently CEO of Altay Therapeutics, meets independence standards and strengthens the company's governance structure.
Key Takeaways
James B. Breitmeyer, M.D., Ph.D. appointed to Board of Directors effective immediately on April 23, 2026
Dr. Breitmeyer currently serves as Chief Executive Officer of Altay Therapeutics, Inc., bringing external leadership experience
2 more takeaways